


# Orelabrutinib (ICP-022)

**ALTERNATE NAME:** ICP022  
2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-4-yl]pyridine-3-carboxamide

**CATALOG #:** B2789-1 1 mg  
B2789-5 5 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>26</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>

**MOLECULAR WEIGHT:** 427.49

**CAS NUMBER:** 1655504-04-3

**APPEARANCE:** Crystalline solid

**PURITY:** ≥98% by HPLC

**SOLUBILITY:** >50 mg/ml DMSO

**DESCRIPTION:** Orelabrutinib is a potent and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.

**STORAGE TEMPERATURE:** -20°C. Protect from light

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

BTK Inhibitor II (B2453)  
Branebrutinib (B2998)  
BTK Inhibitor, PCI-32765 (2298)  
AVL-292 (Spebrutinib) (9413)  
Zanubrutinib (B2512)

**DISCLAIMER:** *FOR RESEARCH USE ONLY! Not to be used on humans.*